Gonadorelin vs LH

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Binds LH receptors on testicular Leydig cells, stimulating the cholesterol → testosterone biosynthetic pathway. In women, the LH surge triggers ovulation and supports luteal phase progesterone production.

LH (luteinizing hormone) is an endogenous heterodimeric glycoprotein hormone produced by pituitary gonadotrophs, sharing the common alpha subunit with FSH, TSH, and hCG, with a unique LH-beta subunit structurally homologous to hCG-beta; LH drives sex steroid synthesis through pulsatile release regulated by hypothalamic GnRH, and mediates the midcycle LH surge that triggers ovulation in women and sustains Leydig cell testosterone production in men. LH activates its receptor (LHR/LHCGR) on ovarian theca cells to stimulate androgen synthesis (which granulosa cells aromatize to estrogen under FSH regulation) and triggers follicular rupture and corpus luteum formation during the ovulatory surge; in men, tonic LH stimulates Leydig cell testosterone biosynthesis through cAMP/StAR pathway activation. A double-blind randomized controlled trial of supplemental recombinant LH (lutropin alfa) during controlled ovarian stimulation for ART demonstrated comparable clinical outcomes to FSH-only protocols in patients with baseline LH deficiency, providing evidence that lutropin alfa can serve as an effective LH substitute in gonadotropin-deficient women undergoing fertility treatment. Lutropin alfa (Luveris; Pergoveris in co-formulation with FSH) is approved in the European Union and several other jurisdictions for stimulation of follicular development in women with profound LH deficiency, but is not broadly approved in the United States; endogenous LH is not used as a therapeutic agent, and hCG — structurally similar to LH with a longer plasma half-life — is typically used as an LH surrogate for ovulation triggering and luteal phase support in US clinical practice.